Advertisement

Table of Contents

Breaking Advances

Review

Priority Reports

Integrated Systems and Technologies

Microenvironment and Immunology

  • Microenvironment and Immunology
    The Planar Cell Polarity Pathway Drives Pathogenesis of Chronic Lymphocytic Leukemia by the Regulation of B-Lymphocyte Migration
    Markéta Kaucká, Karla Plevová, Šárka Pavlová, Pavlína Janovská, Archana Mishra, Jan Verner, Jiřina Procházková, Pavel Krejčí, Jana Kotašková, Petra Ovesná, Boris Tichý, Yvona Brychtová, Michael Doubek, Alois Kozubík, Jiří Mayer, Šárka Pospíšilová and Vítězslav Bryja
    Cancer Res March 1 2013 73 (5) 1491-1501; DOI:10.1158/0008-5472.CAN-12-1752

    A class of molecules regulating cell polarity in circulating chronic lymphocytic leukemia cells mediates key pathogenic interactions with their microenvironment that determine prognosis.

  • Microenvironment and Immunology
    Autoantibody Signatures Involving Glycolysis and Splicesome Proteins Precede a Diagnosis of Breast Cancer among Postmenopausal Women
    Jon J. Ladd, Timothy Chao, Melissa M. Johnson, Ji Qiu, Alice Chin, Rebecca Israel, Sharon J. Pitteri, Jianning Mao, Mei Wu, Lynn M. Amon, Martin McIntosh, Christopher Li, Ross Prentice, Nora Disis and Samir Hanash
    Cancer Res March 1 2013 73 (5) 1502-1513; DOI:10.1158/0008-5472.CAN-12-2560

    Circulating proteins, free autoantibodies, and protein-antibody complexes are defined in breast cancer patients, with possible implications for earlier detection of disease.

  • Microenvironment and Immunology
    Delicate Balance among Three Types of T Cells in Concurrent Regulation of Tumor Immunity
    Liat Izhak, Elena Ambrosino, Shingo Kato, Stanley T. Parish, Jessica J. O'Konek, Hannah Weber, Zheng Xia, David Venzon, Jay A. Berzofsky and Masaki Terabe
    Cancer Res March 1 2013 73 (5) 1514-1523; DOI:10.1158/0008-5472.CAN-12-2567

    Several distinct types of immune regulatory cells influence tumor immunity at the same time in a tumor, but their balance depends on T cells coordinately controlling them, possibly impacting immunotherapeutic strategies.

  • Microenvironment and Immunology | Free Article
    Acidity Generated by the Tumor Microenvironment Drives Local Invasion
    Veronica Estrella, Tingan Chen, Mark Lloyd, Jonathan Wojtkowiak, Heather H. Cornnell, Arig Ibrahim-Hashim, Kate Bailey, Yoganand Balagurunathan, Jennifer M. Rothberg, Bonnie F. Sloane, Joseph Johnson, Robert A. Gatenby and Robert J. Gillies
    Cancer Res March 1 2013 73 (5) 1524-1535; DOI:10.1158/0008-5472.CAN-12-2796

    Striking findings show that tumor invasion into adjacent normal tissues proceeds in the direction of low pH and that simply lowering the acidity of adjacent tissues in vivo by administering sodium bicarbonate is sufficient to block invasion.

Molecular and Cellular Pathobiology

  • Molecular and Cellular Pathobiology
    Id-1 Is a Key Transcriptional Regulator of Glioblastoma Aggressiveness and a Novel Therapeutic Target
    Liliana Soroceanu, Ryuichi Murase, Chandani Limbad, Eric Singer, Juanita Allison, Isabel Adrados, Rumi Kawamura, Arash Pakdel, Yayoi Fukuyo, Daniel Nguyen, Sabeena Khan, Robert Arauz, Garret L. Yount, Dan H. Moore, Pierre-Yves Desprez and Sean D. McAllister
    Cancer Res March 1 2013 73 (5) 1559-1569; DOI:10.1158/0008-5472.CAN-12-1943

    A factor associated previously with angiogenesis support is found to control the aggressiveness and self-renewal potential of glioblastoma, the most common and deadly primary adult brain tumor.

  • Molecular and Cellular Pathobiology
    FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
    Biswajyoti Sahu, Marko Laakso, Päivi Pihlajamaa, Kristian Ovaska, Ievgenii Sinielnikov, Sampsa Hautaniemi and Olli A. Jänne
    Cancer Res March 1 2013 73 (5) 1570-1580; DOI:10.1158/0008-5472.CAN-12-2350

    The findings of this study raise questions about the precise specificity of accepted androgen receptor pathways in castration-resistant prostate tumors under androgen-deprived states.

  • Molecular and Cellular Pathobiology
    ALX1 Induces Snail Expression to Promote Epithelial-to-Mesenchymal Transition and Invasion of Ovarian Cancer Cells
    Hong Yuan, Hiroaki Kajiyama, Satoko Ito, Nobuhisa Yoshikawa, Toshinori Hyodo, Eri Asano, Hitoki Hasegawa, Masao Maeda, Kiyosumi Shibata, Michinari Hamaguchi, Fumitaka Kikkawa and Takeshi Senga
    Cancer Res March 1 2013 73 (5) 1581-1590; DOI:10.1158/0008-5472.CAN-12-2377

    A homeobox transcription factor implicated in mesenchymal differentiation and craniofacial development upregulates the EMT regulator Snail to drive invasion and metastasis.

  • Molecular and Cellular Pathobiology
    Epigenetic Regulator Smchd1 Functions as a Tumor Suppressor
    Huei San Leong, Kelan Chen, Yifang Hu, Stanley Lee, Jason Corbin, Miha Pakusch, James M. Murphy, Ian J. Majewski, Gordon K. Smyth, Warren S. Alexander, Douglas J. Hilton and Marnie E. Blewitt
    Cancer Res March 1 2013 73 (5) 1591-1599; DOI:10.1158/0008-5472.CAN-12-3019

    Results identify a chromatin modifier that may act through the same pathways as MLL chimeric proteins in driving a variety of hematopoietic cancers.

Prevention and Epidemiology

  • Prevention and Epidemiology
    Prospective Analysis of Body Mass Index, Physical Activity, and Colorectal Cancer Risk Associated with β-Catenin (CTNNB1) Status
    Teppei Morikawa, Aya Kuchiba, Paul Lochhead, Reiko Nishihara, Mai Yamauchi, Yu Imamura, Xiaoyun Liao, Zhi Rong Qian, Kimmie Ng, Andrew T. Chan, Jeffrey A. Meyerhardt, Edward Giovannucci, Charles S. Fuchs and Shuji Ogino
    Cancer Res March 1 2013 73 (5) 1600-1610; DOI:10.1158/0008-5472.CAN-12-2276

    Obesity and low physical activity associate with increased risk of colorectal cancers that do not involve β-catenin, the chief target of the WNT pathway, but not risk of β-catenin-positive colorectal cancers, which may be more aggressive.

Therapeutics, Targets, and Chemical Biology

  • Therapeutics, Targets, and Chemical Biology
    Imatinib Radiosensitizes Bladder Cancer by Targeting Homologous Recombination
    Boling Qiao, Martin Kerr, Blaz Groselj, Mark T.W. Teo, Margaret A. Knowles, Robert G. Bristow, Roger M. Phillips and Anne E. Kiltie
    Cancer Res March 1 2013 73 (5) 1611-1620; DOI:10.1158/0008-5472.CAN-12-1170

    The tyrosine kinase inhibitor Gleevec may have additional uses to radiosensitize tumors that are defective in non-homologous end joining (NHEJ), with the potential to greatly expand clinical applications of this agent.

  • Therapeutics, Targets, and Chemical Biology
    Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy
    Rebeka Sultana, Tarek Abdel-Fatah, Rachel Abbotts, Claire Hawkes, Nada Albarakati, Claire Seedhouse, Graham Ball, Stephen Chan, Emad A. Rakha, Ian O. Ellis and Srinivasan Madhusudan
    Cancer Res March 1 2013 73 (5) 1621-1634; DOI:10.1158/0008-5472.CAN-12-2929

    Findings suggest how XRCC1 deficiency in breast cancer can inform choice of targeted chemotherapies for treatment, based on the synthetic lethality that can be achieved with the inhibition of particular mechanisms of DNA double-strand break repair.

Tumor and Stem Cell Biology

  • Tumor and Stem Cell Biology
    HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
    Suthinee Ithimakin, Kathleen C. Day, Fayaz Malik, Qin Zen, Scott J. Dawsey, Tom F. Bersano-Begey, Ahmed A. Quraishi, Kathleen Woods Ignatoski, Stephanie Daignault, April Davis, Christopher L. Hall, Nallasivam Palanisamy, Amber N. Heath, Nader Tawakkol, Tahra K. Luther, Shawn G. Clouthier, Whitney A. Chadwick, Mark L. Day, Celina G. Kleer, Dafydd G. Thomas, Daniel F. Hayes, Hasan Korkaya and Max S. Wicha
    Cancer Res March 1 2013 73 (5) 1635-1646; DOI:10.1158/0008-5472.CAN-12-3349

    HER2 selectively regulates the cancer stem cell population in luminal breast cancers, perhaps explaining the clinical benefits of adjuvant trastuzumab therapy in tumors where the HER2 gene is not amplified.

Back to top
Cancer Research: 73 (5)
March 2013
Volume 73, Issue 5

Sign up for alerts

Issue Highlights

Jump to

Advertisement